← Back
SAN FREDIANO
December, 05th | 14:00 - 15:00
FREE PAPERS - HIGHLIGHTED NEW DRUGS AMD 1
Add to calendar
Chairs: KAISER PETER, LANZETTA PAOLO, VADALÀ MARIA
December, 05th | 14:00 - 14:03
Impact of age and treatment type on hyeperreflective material and hypertransmission into the choroid development in anti-vegf therapy
PETO TUNDE
Add to calendar
Impact of age and treatment type on hyeperreflective material and hypertransmission into the choroid development in anti-vegf therapy
PETO TUNDE
Add to calendar
December, 05th | 14:03 - 14:06
Talon, a phase iiib study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 64-week results
VADALÀ MARIA
Add to calendar
Talon, a phase iiib study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 64-week results
VADALÀ MARIA
Add to calendar
December, 05th | 14:06 - 14:09
Treatment patterns, visual outcomes and safety in eyes with neovascular age-related macular degeneration (namd) and diabetic macular edema (dme) treated with faricimab in the uk: 1-year results from the faricimab real-world evidence (farwide) study
PEARCE IAN
Add to calendar
Treatment patterns, visual outcomes and safety in eyes with neovascular age-related macular degeneration (namd) and diabetic macular edema (dme) treated with faricimab in the uk: 1-year results from the faricimab real-world evidence (farwide) study
PEARCE IAN
Add to calendar
December, 05th | 14:09 - 14:12
Faricimab for polypoidal choroidal vasculopathy: week 16 results from the phase 3b/4 salween trial
CHEUNG GEMMY
Add to calendar
Faricimab for polypoidal choroidal vasculopathy: week 16 results from the phase 3b/4 salween trial
CHEUNG GEMMY
Add to calendar
December, 05th | 14:12 - 14:15
Robust vision gains and anatomical improvement with extended faricimab dosing and potential q20w dosing in treatment-naïve patients with namd in tenaya/lucerne
DHOOT DILSHER
Add to calendar
Robust vision gains and anatomical improvement with extended faricimab dosing and potential q20w dosing in treatment-naïve patients with namd in tenaya/lucerne
DHOOT DILSHER
Add to calendar
December, 05th | 14:15 - 14:18
Reduction in pigment epithelial detachments with faricimab vs aflibercept in patients with treatment-naïve namd: a tenaya/lucerne post hoc analysis
LANZETTA PAOLO
Add to calendar
Reduction in pigment epithelial detachments with faricimab vs aflibercept in patients with treatment-naïve namd: a tenaya/lucerne post hoc analysis
LANZETTA PAOLO
Add to calendar
December, 05th | 14:18 - 14:21
Key baseline disease characteristics in neovascular age-related macular degeneration were not predictive of dosing interval extension of aflibercept 8 mg: a post-hoc 96-week pulsar analysis
ZARRANZ-VENTURA JAVIER
Add to calendar
Key baseline disease characteristics in neovascular age-related macular degeneration were not predictive of dosing interval extension of aflibercept 8 mg: a post-hoc 96-week pulsar analysis
ZARRANZ-VENTURA JAVIER
Add to calendar
December, 05th | 14:21 - 14:24
Pulsar post-hoc analysis: fluid-free status with aflibercept 8mg at weeks 16, 48, and 96 by baseline crt and bcva
PATEL PRAVEEN
Add to calendar
Pulsar post-hoc analysis: fluid-free status with aflibercept 8mg at weeks 16, 48, and 96 by baseline crt and bcva
PATEL PRAVEEN
Add to calendar
December, 05th | 14:24 - 14:27
Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg and 2 mg in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Phase 3 trials
LANZETTA PAOLO
Add to calendar
Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg and 2 mg in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Phase 3 trials
LANZETTA PAOLO
Add to calendar
December, 05th | 14:27 - 14:30
A pulsar phase 3 trial post-hoc analysis: evaluating the timing and magnitude of control of disease activity with aflibercept 8 mg and faricimab, applying similar disease activity criteria across different pivotal phase 3 trials for namd
KAISER PETER
Add to calendar
A pulsar phase 3 trial post-hoc analysis: evaluating the timing and magnitude of control of disease activity with aflibercept 8 mg and faricimab, applying similar disease activity criteria across different pivotal phase 3 trials for namd
KAISER PETER
Add to calendar
December, 05th | 14:30 - 14:33
Clinical impact of the port delivery system with ranibizumab (pds) on fibrosis in patients with neovascular age-related macular degeneration (namd) in the phase 3 archway trial
HEINRICH DOMINIC
Add to calendar
Clinical impact of the port delivery system with ranibizumab (pds) on fibrosis in patients with neovascular age-related macular degeneration (namd) in the phase 3 archway trial
HEINRICH DOMINIC
Add to calendar
